Factors affecting local control, distant recurrence and survival in patients with locally advanced bladder cancer treated by definitive radiotherapy or chemoradiotherapy

Yıl 2006, Cilt: 21 Sayı: 4, 161 - 167, 01.05.2006

Murat Çaloğlu Vuslet Yürüt Çaloğlu Mert Saynak Ruşen Coşar Alas Hakan Karagöl Mustafa Kaplan Kamuran İbiş Cem Uzal

Öz

OBJECTIVES Treatment results of 34 patients with bladder cancer admitted to Department of Radiation Oncology, Medicine Faculty of Trakya University between October 1997 and June 2005 were retrospectively analyzed. Prognostic factors associated with survival were determined. METHODS Their median age was 69 years (range 44-93). Thirty patients (88%) were male and 4 patients (12%) were female. Histopathological diagnosis was transitional cell carcinoma in 20 (59%) patients. Chemotherapy was administered concomitantly with radiotherapy to the 11 (32.35%) of the patients. The median radiotherapy dose was 62.5 (35-68) Gy. The median follow-up was 22 months (5-76 months). Median survival and median disease-free survival were 14.2 months (3.8-57.5) and 10 months (0-55), respectively. RESULTS Three years loco-regional control, metastasis free survival, disease free survival and overall survival rates were 76.5%, 72.2%, 55% and 41.1%, respectively. Epidermoid carcinoma histopathology (p=0.002), not performing concomitant chemotherapy (p=0.003), applying carboplatin instead of cisplatin with radiotherapy (p=0.004) and not conducting complete TURB (p=0.008) were significant poor prognostic factors on loco-regional control. Undifferentiated cell type (p=0.012) and not performing concomitant chemotherapy (p=0.046) were significant adverse factors on distant metastases. Factors that affect overall survival were tumor in stage T4 (p=0.05), hemoglobin value below 10 g/dl (p=0.032) and not performing concomitant chemo-radiotherapy (p=0.017) and complete TURB (p=0.049). CONCLUSION Complications of radiotherapy were acceptable. For the treatment of muscle invasive locally advanced bladder cancer, RT combined with cisplatin is an acceptable treatment option. Moreover, complete TURB before RT is important both for local control and for survival.

Anahtar Kelimeler

Urinary Bladder Neoplasms, Cisplatin, Radiotherapy Dosage, Survival Rate, Retrospective Studies, Disease-Free Survival

Küratif radyoterapi veya kemoradyoterapi ile tedavi edilen lokal ileri mesane kanseri tanılı hastalarda lokal kontrol, uzak yineleme ve sağkalımı etkileyen faktörler

Öz

AMAÇ Ekim 1997-Haziran 2005 tarihleri arasında Trakya Üniversitesi Tıp Fakültesi Radyasyon Onkolojisi Anabilim Dalı'nda küratif amaçlı radyoterapi veya kemoradyoterapi ile tedavi edilen, mesane kanseri tanılı 34 hastanın tedavi sonuçları geriye dönük olarak değerlendirildi. Sağkalımla ilgili olduğu bilinen prognostik faktörler incelendi. GEREÇ VE YÖNTEM Hastaların 30'u (%88) erkek ve 4'ü (%12) kadındı. Medyan yaş 69 idi (44-93). Patolojik tanı 20 hastada (%59) değişici hücreli karsinomdu. Medyan radyoterapi dozu medyan 62.5 Gy'di ve 11 hastaya (%32) eşzamanlı kemoterapi uygulandı. Medyan takip süresi 22 aydı (5-76 ay). Medyan genel sağkalım süresi ve medyan hastalıksız sağkalım süresi 14.2 ay (3.8-57.5 ay) ve 10 aydı (0-55 ay). BULGULAR Hastaların üç yıllık lokal kontrol, uzak metastazsız sağkalım, hastalıksız sağkalım, ve genel sağkalım oranları sırası ile %76.5, %72.2, %55 ve %41.1 bulundu. Lokal kontrolü olumsuz etkilyen faktörler, patolojik tanının epidermoid karsinom olması (p=0.002), eş-zamanlı kemoterapi uygulanmaması (p=0.003), eş-zamanlı tedavide sisplatin yerine karboplatinli kemoterapi uygulanması (p=0.004) ve tam transüretral rezeksiyon (TUR) yapılamamasıydı (p=0.008). İndifferansiye histoloji (p=0.012) ve eş-zamanlı kemoterapi uygulanmaması (p=0.046) uzak yayılımı etkileyen faktörlerdi. T4 evre (p=0.05), hemoglobin değerinin 10'un altında olması (p=0.032) ve eş-zamanlı kemoterapi uyglanmaması (p=0.017) ve tam TUR yapılamaması (p=0.049) genel sağkalımı olumsuz etkileyen faktörler olarak bulundu. SONUÇ Kas invazyonu yapmış lokal ileri evre mesane kanserinin tedavisinde sisplatin ile kombine radyoterapi (RT) kabul edilebilir bir tedavi şeklidir. Hastalara RT öncesi makroskopik total TUR yapılabilmesi lokal kontrol ve sağkalım için önemlidir. Ancak radyokemoterapi adayı olabilecek hastaların seçiminde sonuçları etkileyebilecek bütün faktörlerin değerlendirilmesi gerekmektedir.

Anahtar Kelimeler

Mesane kanseri/mortalite/radyoterapi/tedavi, sisplatin/doz, radyoterapi dozu, sağkalım oranı

Kaynakça

• 1. Bohle A, Jocham D, Bock PR. Intravesical bacillus Calmette-Guerin versus mitomycin C for superficial bladder cancer: a formal meta-analysis of comparative studies on recurrence and toxicity. J Urol 2003;169(1):90-5.
• 2. Shahin O, Thalmann GN, Rentsch C, Mazzucchelli L, Studer UE. A retrospective analysis of 153 patients treated with or without intravesical bacillus CalmetteGuerin for primary stage T1 grade 3 bladder cancer: recurrence, progression and survival. J Urol 2003;169(1):96-100.
• 3. Jemal A, Murray T, Ward E, Samuels A, Tiwari RC, Ghafoor A, et al. Cancer statistics, 2005. CA Cancer J Clin 2005;55(1):10-30.
• 4. George L, Bladou F, Bardou VJ, Gravis G, Tallet A, Alzieu C, et al. Clinical outcome in patients with locally advanced bladder carcinoma treated with conservative multimodality therapy. Urology 2004;64(3):488-93.
• 5. Brennan P, Bogillot O, Cordier S, Greiser E, Schill W, Vineis P, et al. Cigarette smoking and bladder cancer in men: a pooled analysis of 11 case-control studies. Int J Cancer 2000;86(2):289-94.
• 6. Clark PE, Stein JP, Groshen SG, Miranda G, Cai J, Lieskovsky G, et al. The management of urethral transitional cell carcinoma after radical cystectomy for invasive bladder cancer. J Urol 2004;172(4 Pt 1):1342-7.
• 7. Goodman GB, Hislop TG, Elwood JM, Balfour J. Conservation of bladder function in patients with invasive bladder cancer treated by definitive irradiation and selective cystectomy. Int J Radiat Oncol Biol Phys 1981;7(5):569-73.
• 8. Mameghan H, Fisher RJ, Watt WH, Meagher MJ, Rosen IM, Mameghan J, et al. The management of invasive transitional cell carcinoma of the bladder. Results of definitive and preoperative radiation therapy in 390 patients treated at the Prince of Wales Hospital, Sydney, Australia. Cancer 1992;69(11):2771-8.
• 9. Moonen L, vd Voet H, de Nijs R, Hart AA, Horenblas S, Bartelink H. Muscle-invasive bladder cancer treated with external beam radiotherapy: pretreatment prognostic factors and the predictive value of cystoscopic re-evaluation during treatment. Radiother Oncol 1998;49(2):149-55.
• 10. Fossa SD, Waehre H, Aass N, Jacobsen AB, Olsen DR, Ous S. Bladder cancer definitive radiation therapy of muscle-invasive bladder cancer. A retrospective analysis of 317 patients. Cancer 1993;72(10):3036-43.
• 11. Reuter VE. Pathology of bladder cancer: assessment of prognostic variables and response to therapy. Semin Oncol 1990;17(5):524-32.
• 12.Rogers CG, Palapattu GS, Shariat SF, Karakiewicz PI, Bastian PJ, Lotan Y, et al. Clinical outcomes following radical cystectomy for primary nontransitional cell carcinoma of the bladder compared to transitional cell carcinoma of the bladder. J Urol 2006;175(6):2048- 53.
• 13. Fokdal L, Hoyer M, von der Maase H. Treatment outcome and prognostic variables for local control and survival in patients receiving radical radiotherapy for urinary bladder cancer. Acta Oncol 2004;43(8):749- 57.
• 14. Hayter CR, Paszat LF, Groome PA, Schulze K, Math M, Mackillop WJ. A population-based study of the use and outcome of radical radiotherapy for invasive bladder cancer. Int J Radiat Oncol Biol Phys 1999;45(5):1239-45.
• 15. Duncan W, Quilty PM. The results of a series of 963 patients with transitional cell carcinoma of the urinary bladder primarily treated by radical megavoltage Xray therapy. Radiother Oncol 1986;7(4):299-310.
• 16. Harada K, Sakai I, Kurahashi T, Muramaki M, Yamanaka K, Hara I, et al. Clinicopathological features of recurrence after radical cystectomy for patients with transitional cell carcinoma of the bladder. Int Urol Nephrol 2006;38(1):49-55.
• 17. Sauer R, Birkenhake S, Kuhn R, Wittekind C, Schrott KM, Martus P. Efficacy of radiochemotherapy with platin derivatives compared to radiotherapy alone in organ-sparing treatment of bladder cancer. Int J Radiat Oncol Biol Phys 1998;40(1):121-7.
• 18.Rodel C, Grabenbauer GG, Kuhn R, Papadopoulos T, Dunst J, Meyer M, et al. Combined-modality treatment and selective organ preservation in invasive bladder cancer: long-term results. J Clin Oncol 2002;20(14):3061-71.
• 19.Coppin CM, Gospodarowicz MK, James K, Tannock IF, Zee B, Carson J, et al. Improved local control of invasive bladder cancer by concurrent cisplatin and preoperative or definitive radiation. The National Cancer Institute of Canada Clinical Trials Group. J Clin Oncol 1996;14(1):2901-7.
• 20.Rodel C, Weiss C, Sauer R. Organ preservation by combined modality treatment in bladder cancer: the European perspective. Semin Radiat Oncol 2005;15(1):28-35.
• 21. Mameghan H, Fisher RJ, Watt WH, Meagher MJ, Rosen IM, Mameghan J, et al. The management of invasive transitional cell carcinoma of the bladder. Results of definitive and preoperative radiation therapy in 390 patients treated at the Prince of Wales Hospital, Sydney, Australia. Cancer 1992;69(11):2771-8.
• 22. Pollack A, Zagars GK, Swanson DA. Muscle-invasive bladder cancer treated with external beam radiotherapy: prognostic factors. Int J Radiat Oncol Biol Phys 1994;30(2):267-77.
• 23. Salminen E. External beam radiation treatment of urinary bladder carcinoma. An analysis of results in 203 patients. Acta Oncol 1990;29(7):909-14.
• 24.Chahal R, Sundaram SK, Iddenden R, Forman DF, Weston PM, Harrison SC. A study of the morbidity, mortality and long-term survival following radical cystectomy and radical radiotherapy in the treatment of invasive bladder cancer in Yorkshire. Eur Urol 2003;43(3):246-57.
• 25. Harrison LB, Chadha M, Hill RJ, Hu K, Shasha D. Impact of tumor hypoxia and anemia on radiation therapy outcomes. Oncologist 2002;7(6):492-508.
• 26. Harrison LB, Shasha D, White C, Ramdeen B. Radiotherapy-Associated Anemia: The Scope of the Problem. Oncologist 2000;5 Suppl 2:1-7.
• 27. Folkman J. Seminars in Medicine of the Beth Israel Hospital, Boston. Clinical applications of research on angiogenesis. N Engl J Med 1995;333(26):1757-63.
• 28. Girinski T, Pejovic-Lenfant MH, Bourhis J, Campana F, Cosset JM, Petit C, et al. Prognostic value of hemoglobin concentrations and blood transfusions in advanced carcinoma of the cervix treated by radiation therapy: results of a retrospective study of 386 patients. Int J Radiat Oncol Biol Phys 1989;16(1):37- 42.
• 29. Gospodarowicz MK, Hawkins NV, Rawlings GA, Connolly JG, Jewett MA, Thomas GM, et al. Radical radiotherapy for muscle invasive transitional cell carcinoma of the bladder: failure analysis. J Urol 1989;142(6):1448-54.
• 30. Greven KM, Solin LJ, Hanks GE. Prognostic factors in patients with bladder carcinoma treated with definitive irradiation. Cancer 1990;65(4):908-12.
• 31. Speight JL, Roach M 3rd. Radiotherapy in the management of common genitourinary malignancies. Hematol Oncol Clin North Am 2006;20(2):321-46.
• 32. Tonoli S, Bertoni F, De Stefani A, Vitali E, De Tomasi D, Caraffini B, et al. Radical radiotherapy for bladder cancer: retrospective analysis of a series of 459 patients treated in an Italian institution. Clin Oncol (R Coll Radiol) 2006;18(1):52-9.